Related Experiment Videos
[Triple immunosuppression in renal transplantation in children: 3 years' experience]
1Department of Paediatric Nephrology, Royal Free Hospital, London, England.
Insights
Cyclosporin A, a key immunosuppressant, did not significantly impact renal transplant graft survival rates in children. Vascular complications, not immunosuppressive therapy, were linked to graft loss in this study.
Area of Science:
- Pediatric Nephrology
- Transplantation Immunology
- Immunosuppressive Therapy
Context:
- Pediatric renal transplantation is crucial for end-stage renal disease.
- Optimizing immunosuppression is vital for long-term graft survival.
- Cyclosporin A is a cornerstone of post-transplant immunosuppression.
Purpose:
- To evaluate the impact of Cyclosporin A on graft survival in pediatric renal transplant recipients.
- To assess the influence of different Cyclosporin A administration routes (IV vs. oral) on outcomes.
- To identify factors contributing to graft loss, including immunosuppressive agents and vascular complications.
Summary:
- Fifty children received 53 renal transplants, treated with Cyclosporin A, low-dose steroids, and azathioprine.
- Graft survival rates were 82% at 1 and 2 years, with no significant difference based on Cyclosporin A's administration route.
- Vascular complications, not the immunosuppressive regimen, were associated with the loss of 4 grafts, particularly those from young donors.
Impact:
- This study suggests that Cyclosporin A's administration route does not significantly affect renal graft survival in pediatric patients.
- Findings highlight the critical role of vascular complications in graft failure, independent of immunosuppression type.
- Results inform clinical practice regarding immunosuppressive strategies and monitoring for vascular issues in pediatric renal transplantation.
Abstract:
Cyclosporin A in combination with low-dose steroid therapy and azathioprine was given to 50 children who received 53 renal transplants. In spite of a limited period of observation, the use of cyclosporin A, either on a post operative intravenous regime or on oral regime when primary graft function is achieved, has no significant influence on graft survival rate, which is 82% after 1 and 2 years, utilising cadaver donors. Vascular complications were responsible for the loss of 4 grafts and were associated with the use of kidneys from young donors, rather than the type of immunosuppressive agents used.